Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria, including Acinetobacter species; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic for the treatment of acute bacterial skin related
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-31.16%||Sales Growth - Q/Q||-33.76%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-0.97%||ROE||-2.21%||ROI||-1.29%|
|Current Ratio||2.51||Quick Ratio||2.15||Long Term Debt/Equity||1.06||Debt Ratio||0.35|
|Gross Margin||62.22%||Operating Margin||-13.51%||Net Profit Margin||-3.29%||Dividend Payout Ratio|
|Cash From Financing Activities||397.92 M||Cash From Investing Activities||-119.38 M||Cash From Operating Activities||-41.03 M||Gross Profit||53.47 M|
|Net Profit||-46.59 M||Operating Profit||-78.99 M||Total Assets||2.29 B||Total Current Assets||881.74 M|
|Total Current Liabilities||351.44 M||Total Debt||562.73 M||Total Liabilities||1.29 B||Total Revenue||90.47 M|
|High 52 week||40.94||Low 52 week||17.26||Last close||25.01||Last change||2.75%|
|RSI||56.55||Average true range||0.91||Beta||0.97||Volume||390.36 K|
|Simple moving average 20 days||5.42%||Simple moving average 50 days||18.84%||Simple moving average 200 days||-15.39%|
|Performance Week||0.97%||Performance Month||24.06%||Performance Quart||22.36%||Performance Half||-36.28%|
|Performance Year||-16.16%||Performance Year-to-date||30.67%||Volatility daily||2.3%||Volatility weekly||5.15%|
|Volatility monthly||10.55%||Volatility yearly||36.55%||Relative Volume||137.41%||Average Volume||1.3 M|
|New High||New Low|
2019-03-18 18:51:10 | Alnylam's ALNY Impressive Pipeline Drives Share Price
2019-03-15 16:24:16 | Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
2019-03-12 10:18:02 | Implied Volatility Surging for Medicines Company MDCO Stock Options
2019-03-12 09:59:01 | Alnylam Files Application for Hypertension Candidate in UK
2019-03-10 19:14:42 | Insider Buys Of The Week: Arconic, CenturyLink, Hain Celestial and More
2019-03-08 16:32:33 | Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?
2019-03-08 08:59:00 | Insider Buying Is Still Alive and Well at These 3 Companies
2019-03-08 02:08:55 | [$$] A disease in remission? New hope in the quest to cure HIV
2019-03-07 09:00:02 | Alnylam Stock Down Despite Positive Phase III Givosiran Data
2019-02-28 09:50:02 | Medicines Company MDCO Q4 Loss Widens, Inclisiran in Focus
2019-02-28 02:29:01 | Edited Transcript of MDCO earnings conference call or presentation 27-Feb-19 1:30pm GMT
2019-02-27 12:57:01 | Medicines Co MDCO Q4 2018 Earnings Conference Call Transcript
2019-02-21 07:00:00 | The Medicines Company Announces Upcoming Investor Conference Presentations
2019-02-13 10:31:03 | Will Medicines Co. MDCO Report Negative Q4 Earnings? What You Should Know
2019-02-08 08:54:01 | Is the Options Market Predicting a Spike in Medicines Company MDCO Stock?
2019-02-08 08:06:28 | See what the IHS Markit Score report has to say about Medicines Co.
2019-02-08 07:50:39 | [$$] FT Health: Combating cancer; Brexit and EU medicine verification
2019-02-08 07:47:12 | Alnylam's ALNY Q4 Earnings and Revenues Beat Estimates
2019-02-01 06:47:01 | [$$] FT Health: Is Big Food ripe for the Big Tobacco treatment?
2019-01-30 08:10:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Economic Growth
2019-01-29 08:02:40 | See what the IHS Markit Score report has to say about Medicines Co.
2019-01-28 01:11:50 | [$$] UK shows leadership on anti-microbial resistance
2019-01-22 14:38:42 | Need To Know: The Medicines Company NASDAQ:MDCO Insiders Have Been Buying Shares
2019-01-18 05:00:00 | Top Picks 2019- The Medicines Company MDCO
2019-01-15 08:06:21 | See what the IHS Markit Score report has to say about Medicines Co.
2019-01-09 08:07:05 | See what the IHS Markit Score report has to say about Medicines Co.
2019-01-04 05:00:25 | [$$] British schools explore EU expansion after Brexit
2019-01-03 08:42:01 | Implied Volatility Surging for Medicines Company MDCO Stock Options
2018-12-24 09:29:02 | Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III
2018-12-23 09:42:53 | Insider Buys Of The Week: Chesapeake Energy, Medicines Company, NuStar Energy
2018-12-20 08:06:53 | See what the IHS Markit Score report has to say about Medicines Co.
2018-12-18 18:15:03 | The Medicines Co MDCO CEO Mark Timney Bought $499,652 of Shares
2018-12-13 22:52:48 | Is The Medicines Company MDCO A Good Stock To Buy?
2018-12-13 21:43:00 | The Medicines Company Prices $150 Million of Convertible Notes
2018-12-13 17:37:00 | Here's Why Shares of The Medicines Company Sank 14.5% Today
2018-12-12 16:30:00 | The Medicines Company Announces Intention to Offer $150 Million of Convertible Notes
2018-12-11 07:28:00 | The Medicines Co. names Mark Timney CEO effective immediately
2018-12-11 07:23:00 | The Medicines Company Appoints Mark Timney as Chief Executive Officer
2018-12-08 09:30:02 | Medicines Co. MDCO Down 11% Since Last Earnings Report: Can It Rebound?
2018-12-06 23:29:05 | [$$] Health sector warned of 6-month medicine shortages in no-deal
2018-12-04 08:06:55 | See what the IHS Markit Score report has to say about Medicines Co.
2018-12-03 23:00:46 | [$$] Government prepares to ration ferry space under no-deal Brexit
2018-12-03 23:00:28 | [$$] Flexibility on cancer drugs approval will foster innovation
2018-11-27 08:07:26 | See what the IHS Markit Score report has to say about Medicines Co.
2018-11-22 08:07:05 | See what the IHS Markit Score report has to say about Medicines Co.
2018-11-21 23:03:27 | [$$] The Brexit political declaration: the key points